title: Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia.
abstract: We sought to determine if inhaled nitric oxide (iNO) administered to preterm infants with premature rupture of membranes (PPROM), oligohydramnios, and pulmonary hypoplasia improved oxygenation, survival, or other clinical outcomes. Data were analyzed from infants with suspected pulmonary hypoplasia, oligohydramnios, and PPROM enrolled in the National Institute of Child Health and Development Neonatal Research Network Preemie Inhaled Nitric Oxide (PiNO) trial, where patients were randomized to receive placebo (oxygen) or iNO at 5 to 10 ppm. Outcome variables assessed were PaO (2) response, mortality, bronchopulmonary dysplasia (BPD), and severe intraventricular hemorrhage (IVH) or periventricular leukomalacia (PVL). Twelve of 449 infants in the PiNO trial met criteria. Six infants received iNO and six received placebo. The iNO group had a mean increase in PaO (2) of 39 +/- 50 mm Hg versus a mean decrease of 11 +/- 15 mm Hg in the control group. Mortality was 33% versus 67%, BPD (2/5) 40% versus (2/2) 100%, and severe IVH or PVL (1/5) 20% versus (1/2) 50% in the iNO and control groups, respectively. None of these changes were statistically significant. Review of a limited number of cases from a large multicenter trial suggests that iNO use in the setting of PPROM, oligohydramnios, and suspected pulmonary hypoplasia improves oxygenation and may decrease the rate of BPD and death without increasing severe IVH or PVL. However, the small sample size precludes definitive conclusions. Further studies are required to determine if iNO is of benefit in this specific patient population.
authors.affiliation: Division of Neonatology, Stanford University, Stanford, California, USA. vchock@stanford.edu
authors.forename: Valerie Y
authors.initials: VY
authors.lastname: Chock
authors.forename: Krisa P
authors.initials: KP
authors.lastname: Van Meurs
authors.forename: Susan R
authors.initials: SR
authors.lastname: Hintz
authors.forename: Richard A
authors.initials: RA
authors.lastname: Ehrenkranz
authors.forename: James A
authors.initials: JA
authors.lastname: Lemons
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Kendrick
authors.forename: David K
authors.initials: DK
authors.lastname: Stevenson
mesh_terms: D000280:Administration, Inhalation; D001997:Bronchopulmonary Dysplasia / Q000209:etiology / Q000401:mortality* / Q000628:therapy*; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000175:diagnosis / Q000628:therapy; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage*; D016104:Oligohydramnios / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D010865:Pilot Projects; D011247:Pregnancy; D011336:Probability; D012016:Reference Values; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D009569:Nitric Oxide